Head & neck cancers trials

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers is being studied. Conditions: Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers +3 • Eligibility: * INCLUSION CRITERIA: * Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \& Neck…. Goal: Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests GV20-0251 to see if it is safe in adults with advanced or refractory solid tumors. It is a single-center, single-arm early-stage trial at West China Hospital. It uses a 3+3 dose-escalation design, starting with 10 mg/kg and 20 mg/kg given every three weeks, to find a tolerable dose and watch for dose-limiting toxicities. The trial covers multiple solid tumor types to learn about safety and dosing across indications. Key exclusions include active infections, certain heart problems or QT prolongation, autoimmune disease needing immunosuppressive therapy, HIV/HBV/HCV infections, pregnancy, and recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment is being studied. Conditions: Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms +1 • Eligibility: Inclusion Criteria: * Diagnosis of cancer in either the adjuvant or metastatic setting requiring initial therapy with 5-FU or Capecitabine. * DPYD testing performed by a CLIA-certified laboratory…. Goal: To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm. Phase/Status/Sponsor: Unknown phase; RECRUITING; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer is being studied. Conditions: Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma +16 • Eligibility: Inclusion Criteria: * Age 18 or over * Histologically or cytologically documented advanced or metastatic cancer that has relapsed from or is refractory to standard treatment in two…. Goal: Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether a 3D mindfulness virtual reality program is feasible and acceptable compared with a 2D non-immersive VR program for reducing depression, anxiety, pain, and stress in adults with head and neck cancer undergoing chemoradiation and their caregivers. It also looks for preliminary evidence that these VR approaches can lower depressive symptoms, anxiety, and pain and which method participants prefer. Eligible participants are adults 18 and older with head and neck cancer scheduled for chemoradiation and their identified caregivers who can consent in English and complete surveys. Exclusions include serious mental illness, prior head and neck cancer treatment, a history of psychiatric treatment (antidepressants, PTSD), chronic pain, and sensory or cognitive impairments that would prevent using the VR or completing surveys.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of DF6215 in Patients with Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Solid Tumor Cancer • Eligibility: Key Inclusion Criteria * Male or female patients ≥ 18 years old. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * An estimated life…. Goal: A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors; is designed to assess the safety, tolerability, and preliminary efficacy of DF6215 alone or in combination with pembrolizumab in patients with advanced solid tumors. The study is open-label, meaning both participants and investigators are aware of the treatment being administered. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dragonfly Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests a topical spray containing superoxide dismutase (SOD) to help prevent radiation dermatitis. - It is for adults with non-metastatic head and neck cancer who are planned to receive high‑dose radiotherapy, either as the main treatment or after surgery. - Researchers want to learn whether the SOD spray reduces how often and how severe skin damage from radiation is, when it starts, and how it affects symptoms, quality of life, treatment interruptions, and safety. - Key exclusions include poor overall health or skin problems in the treatment area, allergies to trolamine or fullerene, inflammatory or connective tissue skin disorders, and a history of head and neck radiotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors is being studied. Conditions: Hepatocarcinoma, Lung Cancer, Melanoma +7 • Eligibility: Inclusion Criteria: 1. Cytohistological confirmation is required for diagnosis of cancer. 2. Signed informed consent before recruiting. 3. Age above 18 years with estimated survival over 3 months.…. Goal: This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences. Phase/Status/Sponsor: Unknown phase; RECRUITING; Second Affiliated Hospital of Guangzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests Pedmark sodium thiosulfate to protect against cisplatin-related hearing loss. - It is for adults with cancer who have not been treated yet and are going to receive a cisplatin-based chemotherapy regimen. - The study aims to learn whether sodium thiosulfate is safe and effective at reducing hearing impairment in adults, an use already shown in children but less studied in adults. - Key exclusions include prior cisplatin exposure, planned head or neck radiation, pregnancy or breastfeeding, ongoing ototoxic medications, and certain electrolyte problems.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intratumoral N17350 in Advanced Solid Tumors is being studied. Conditions: Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin +4 • Eligibility: Inclusion Criteria: 1. Age ≥18 years (or legal age of consent in the study jurisdiction). 2. Able to provide written informed consent and willing/able to comply with study…. Goal: The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Onchilles Pharma Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) +6 • Eligibility: Inclusion Criteria: Part A, B, and C: * Written informed consent, dated and signed by the patient prior to any study-specific procedure. * Part B and C are…. Goal: The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC. Phase/Status/Sponsor: Unknown phase; RECRUITING; ITM Oncologics GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors is being studied. Conditions: Solid Tumours, Sarcoma, HNSCC +9 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed disease, locally advanced or metastatic: For Phase 1a: Solid tumor with a COX2-associated immunosuppressive pathway, for which standard treatment options are…. Goal: The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; Epkin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether starting swallowing and speech therapy early after tongue cancer surgery is feasible and could help patients’ health and daily function. - It is for adults newly diagnosed with tongue squamous cell carcinoma (at least T2) planned for partial glossectomy with free flap reconstruction who are expected to eat by mouth after surgery and who speak English. - Researchers will compare outcomes before treatment and about one month after treatment to see potential benefits of the early intervention. - Exclusion: patients planned for total glossectomy are not eligible. - The study is recruiting and sponsored by University Health Network, Toronto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests adaptive radiotherapy (ART) for head and neck cancer in a prospective randomized design. - It is for patients with head and neck cancer who have an ECOG score of 0–1 and no prior cancer treatment. - The study aims to learn whether ART provides better outcomes compared with standard radiotherapy. - Key exclusions are ECOG 2–4 or a history of prior cancer treatment. - The trial is sponsored by University Hospital, Essen and is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests pencil beam scanning proton therapy using different doses and schedules to treat tumors that have come back in people who were previously treated with radiation to the same area. - It is for adults 18 years and older with a history of prior radiation and a good performance status (ECOG 0-2). - The researchers want to learn whether this targeted proton therapy can treat the cancer effectively while sparing healthy tissue, compared with past treatment approaches. - Exclusions include people with active non-cancer systemic diseases that would preclude treatment or follow-up, most prior invasive cancers unless disease-free for at least 3 years, and those with active connective tissue disorders such as lupus or scleroderma.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors is being studied. Conditions: HNSCC, Melanoma, Gynecologic Cancer +3 • Eligibility: Inclusion Criteria * Participants must have signed and dated a current IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. Patients must have the…. Goal: The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies. The TIL selection process is based on evidence showing that CD8+ TIL which co-express both CD39 and CD103 harbor the bulk of tumor-reactivity and that the remaining CD8 TIL is mainly composed of non-tumor reactive bystander cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AgonOx, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether Botox injections into the masticatory (chewing) muscles after radiotherapy can help people with trismus from head and neck cancer. It is for adults over 18 who finished radiotherapy at least 3 months ago and have mouth opening of 3.5 cm or less with tightness or pain in these muscles. The Botox injections are given along with oral rehabilitation exercises to reduce muscle tension and spasms and to improve mouth opening, pain, and quality of life. The study will measure mouth opening, trismus status, pain, and quality of life to determine efficacy, and it is currently recruiting; exclusions include prior surgery on the masticatory muscles, severe muscle atrophy or fibrosis, active tumor recurrence, or unstable vital signs.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of On-Couch CBCT Image Quality is being studied. Conditions: Head and Neck Cancer, Thoracic Cancer, Abdominal Cancer +1 • Eligibility: Inclusion Criteria: * Patient age is ≥ 18 years old. * Patient has a diagnosis of primary or metastatic cancer, including but not limited to tumors arising from…. Goal: This is a prospective, single-arm, single-site study designed to generate data describing the image quality and applicability/useability of a high-performance, on-couch CBCT imaging technology (HyperSight) in patients receiving radiation treatment for cancer on a C-arm linear accelerator (TrueBeam). Phase/Status/Sponsor: Unknown phase; RECRUITING; Varian, a Siemens Healthineers Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients is being studied. Conditions: Head and Neck Cancer, Urologic Cancer, Lung Cancer +2 • Eligibility: Inclusion Criteria: * 18 years of age or older * Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications * Written informed consent signed…. Goal: The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Assistance Publique Hopitaux De Marseille.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Smoking Cessation Treatment for Head & Neck Cancer Patients is being studied. Conditions: Head and Neck Cancer, Smoking Cessation • Eligibility: Inclusion Criteria: 1. Current or history of head and neck, lung, breast, gastrointestinal, or genitourinary cancer 2. Age 18 or older 3. Smoking 1 cigarette or more per…. Goal: This is Part 1 of a 2-part research study. The goal of this part of the study is to plan and test an investigational type of counseling called Acceptance and Commitment Therapy, for use in patients who have or had head and neck cancer, lung cancer, breast cancer, gastrointestinal cancer, or genitourinary cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a new combination therapy for HPV-16–associated head and neck cancer, using the ISA101b vaccine with pembrolizumab and cisplatin-based chemoradiotherapy. It is for adults newly diagnosed with intermediate-risk, HPV-16–positive oropharyngeal squamous cell carcinoma, with no distant metastasis. The study aims to learn whether this treatment improves survival, and there is no separate control group. Key exclusions include distant metastases, prior anti-PD-1/PD-L1 therapy, active autoimmune disease requiring systemic treatment, active infection, or pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is being studied. Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +13 • Eligibility: Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via…. Goal: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This multicenter observational study tests how the immune system and nutrition/metabolism affect outcomes for people with head and neck cancer treated with radiotherapy. Participants are adults with newly diagnosed head and neck cancer who will be followed before, during, and up to 24 months after treatment, with measurements of immune markers in tumor tissue and blood, body composition, metabolism, and patient-reported outcomes. The aim is to identify immune and metabolic factors and biomarkers that predict survival, treatment response, and nutritional problems, which could help guide personalized care. Inclusion criteria are newly diagnosed head and neck cancer with a WHO performance status of 0-2; exclusion criteria include previous cancer (except skin cancer), severe alcohol abuse, psychiatric disorder, or inability to understand Swedish. Status: ACTIVE_NOT_RECRUITING.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial will observe whether adults with head and neck cancer adhere to a medically certified cannabis plan during chemoradiation and how they seek health care. - It targets people with histologically confirmed squamous cell carcinoma of the head and neck who are planned for definitive or adjuvant chemoradiation and are willing to use cannabis as directed. - The study aims to learn what factors affect adherence and health-seeking behavior during treatment. - Key exclusions include prior cannabis use disorder, current opioid use disorder on maintenance therapy, current active use of smoked cannabis with unwillingness to stop non-medically certified cannabis, allergy to cannabis derivatives, and uncontrolled illnesses or psychiatric issues that could affect participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This randomized study tests whether a preventive jaw- and swallowing exercise program given before and during radiotherapy helps preserve jaw and swallowing function in head and neck cancer patients. It includes people with tumors of the oropharynx, larynx, or hypopharynx who are planned to receive curative radiotherapy, with or without chemotherapy. All participants will be encouraged to eat or drink for as long as possible during treatment and will have weekly sessions with a speech-language therapist. Exclusion criteria include prior head and neck cancer surgery or treatment, tracheostomy, no teeth, inability to perform the exercise program, inability to complete Swedish questionnaires, or other neurologic or neuromuscular disease.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study is being studied. Conditions: Head and Neck Cancer, Melanoma, Breast Cancer +4 • Eligibility: Inclusion Criteria: 1. Male or female aged ≥ 18 and ≤ 75 years; 2. Patients with advanced malignant solid tumors, histologically or cytologically confirmed, who have failed standard…. Goal: This is an open-label, dose escalation study of the safety and tolerability of Recombinant oncolytic adenovirus L-IFN injection（YSCH-01） when administered via intratumoral injection in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase 1 dose for further study. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Shanghai Fengxian District Central Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 is being studied. Conditions: Head and Neck Squamous Cell Carcinoma • Eligibility: Inclusion Criteria: * 1\) Voluntarily sign written informed consent before screening; 2) Age ≥18 years old; 3) ECOG physical status score 0-1; 4) Histologically or cytologically confirmed squamous…. Goal: This trial is main evaluate the efficacy and safety of Pembrolizumab combined with Anlotinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma with CPS≥1 Phase/Status/Sponsor: Unknown phase; UNKNOWN; Shi Yuankai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Sarcoma, HNSCC +4 • Eligibility: Inclusion Criteria: * 1\. Age 18\~70 years Part I ; Age 18 years or older (Part II and III ). 2. Histologically or pathologically confirmed diagnosis of locally…. Goal: A Phase I/IIa Study of the Safety and Tolerability of T3011 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors Phase/Status/Sponsor: Unknown phase; UNKNOWN; ImmVira Pharma Co. Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor is being studied. Conditions: NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer +8 • Eligibility: Inclusion Criteria: * Age 18 years or older * At least one evaluable or measurable lesion according to RECIST v1.1 * Patient with advanced metastatic solid tumor with…. Goal: Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128 clinical trial or have other considerations that prevent access to MCLA-128 through an existing clinical trial. Participating sites will be added as they apply for and are approved for the EAP. Phase/Status/Sponsor: Unknown phase; APPROVED_FOR_MARKETING; Merus B.V..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers is being studied. Conditions: Urothelial Carcinoma, Head and Neck Cancer, Melanoma +1 • Eligibility: Inclusion Criteria: 1. Subject is ≥18 to ≤75 years of age at the time of signing the study informed consent. 2. Subject has histologically confirmed diagnosis of any…. Goal: This Phase 1 study is designed as a cell dose escalation trial in HLA-A\*02:01 and HLA-A\*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors. The study will enroll subjects between the ages of 18 and 75 using a modified 3+3 cell dose escalation design, to evaluate dose limiting toxicities and determine the target cell dose range. Phase/Status/Sponsor: Unknown phase; COMPLETED; Adaptimmune.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase I study of WM-S1-030 in adults with advanced solid tumors to learn about safety, how the drug behaves in the body, and whether there are early signs it may help. The trial has two parts: a dose-escalation phase to find a safe and potentially active dose, and a dose-expansion phase to gather more safety data and look for anti-tumor activity. It uses oral WM-S1-030 as monotherapy in patients whose cancer is unresectable or metastatic and has progressed after standard therapy or for whom no effective standard treatment exists. Eligible participants need at least one measurable lesion, good overall health (ECOG 0-2), and agree to biopsies, plus adequate organ function and a life expectancy of at least 12 weeks. Key exclusions include prior treatment with RON or MET inhibitors, recent chemotherapy or radiation, active infections or uncontrolled health issues, certain eye or CNS metastases, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

WeCanManage. An mHealth Self-management Tool is being studied. Conditions: Breast Cancer, Head and Neck Cancer, Sarcoma • Eligibility: Inclusion Criteria: Usability Testing of the WeCanManage High Fidelity Prototype * Age 18 or older * Diagnosis of breast cancer, head and neck cancer or sarcoma * Completion…. Goal: Examine the Feasibility, Acceptability, User Satisfaction, and Response Patterns and Preliminary Efficacy on Targeted Patient Reported Outcomes. Using a pre-post, single arm feasibility design with cancer survivors with disabilities Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Illinois at Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether people with advanced solid tumors who have stable disease can stop PD-1/PD-L1 treatment after one year without harming outcomes. It is for patients being treated with PD-1/PD-L1 drugs (like pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab). Participants are randomly assigned to stop treatment after about one year or continue treatment until the cancer progresses, to learn the best length of therapy. To join, patients must have at least stable disease on scans within six weeks of randomization; those with progressive disease before randomization or immune-related toxicity that prevents staying on therapy beyond one year are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of [225Ac]-FPI-1434 Injection is being studied. Conditions: Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer +7 • Eligibility: Inclusion Criteria: 1. Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated,…. Goal: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent). Phase/Status/Sponsor: Unknown phase; TERMINATED; Fusion Pharmaceuticals Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 is being studied. Conditions: Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma +8 • Eligibility: Inclusion Criteria: INT230-6 monotherapy Cohorts EC2 and EC3, combination with KEYTRUDA® cohort DEC2 and combination with Yervoy cohort FEC. Where criteria diverge the DEC2 and FEC specific criteria…. Goal: This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Phase/Status/Sponsor: Unknown phase; COMPLETED; Intensity Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. is being studied. Conditions: Consent Form, Lung Cancer, Colon Cancer +3 • Eligibility: 1. Adult cancer patients (\>18). 2. Patients who suffered with pruritus, or rash or photosensitivity, in the onset of the symptoms. 3. Willing to participate. 4. Ability to…. Goal: The main adverse reaction of EGFR seen in patients is rash. EGFR treated patients have a 24-95% incidence of rash depending on the type of treatment they receive. Phase/Status/Sponsor: Unknown phase; COMPLETED; Cyprus University of Technology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Metastatic Cancer, Solid Tumor, Pancreatic Cancer +3 • Eligibility: Inclusion Criteria: Part 1 1. Written Informed Consent (mentally competent patient, able to understand and willing to sign the informed consent form) 2. Age ≥ 18 years, male…. Goal: A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors Phase/Status/Sponsor: Unknown phase; COMPLETED; PureTech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL is being studied. Conditions: Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer +2 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable tumors 2. Patients demonstrating disease progression after treatment with approved therapies that are known…. Goal: The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL). The antitumor activity of CX-2029 will be evaluated in subjects with head and neck squamous cell carcinoma (HNSCC), DLBCL, non-small cell lung cancer (NSCLC) (squamous cell histology only), or esophageal (esophageal adenocarcinoma \[EAC\], esophageal squamous cell carcinoma \[ESCC\], or gastroesophageal \[GE\] junction) cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; CytomX Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety Study of MGA271 in Refractory Cancer is being studied. Conditions: Prostate Cancer, Melanoma, Renal Cell Carcinoma +4 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed carcinoma (prostate cancer, renal cell carcinoma, head and neck cancer, triple-negative breast cancer, bladder cancer, non-small cell lung cancer) or melanoma…. Goal: The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; MacroGenics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors is being studied. Conditions: Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer +4 • Eligibility: DISEASE CHARACTERISTICS: * Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer with clinical, radiological, or histologic evidence of incurability * Patients with thyroid…. Goal: RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Ottawa Regional Cancer Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer is being studied. Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer +9 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following: * Histologically confirmed advanced primary or malignant solid tumor refractory to standard therapy or for which no curative standard…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with refractory advanced solid tumors or hematologic cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor is being studied. Conditions: Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer +3 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor * Progressive disease on standard therapy, including: * Locally advanced, unresectable primary or recurrent tumor OR * Metastatic disease * Previously…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors is being studied. Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer +6 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignant solid tumor that involves an activated Ras/Raf/MAPK pathway, including the following: * Breast cancer * Prostate cancer * Colon cancer * Pancreatic…. Goal: RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Medicine and Dentistry of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests CDX-585 in people with advanced solid tumors to find the maximum tolerated dose and to assess safety, tolerability, and signs of effectiveness. - It uses dose-escalation and expansion phases, with an expansion portion studying safety at the chosen dose in selected tumor types. - Eligible participants are patients with recurrent, locally advanced, or metastatic solid tumors who have had standard therapy and have measurable disease. - Key exclusions include severe allergic reactions to monoclonal antibodies, prior anti-ILT4 or anti-PD-1/PD-L1 therapies, active autoimmune disease or pneumonitis, untreated active CNS metastases, recent thrombotic events, or certain other prior cancers.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible…. Goal: This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Actym Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene is being studied. Conditions: HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification +41 • Eligibility: Inclusion Criteria: Phase I Patients must meet the following criteria for inclusion into the study: 1. Patients must be able to provide documented voluntary informed consent. 2. Male…. Goal: Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. Phase/Status/Sponsor: Unknown phase; COMPLETED; Klus Pharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors is being studied. Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor +2 • Eligibility: Inclusion Criteria: * Signed informed consent * Subjects must be ≥ 18 years of age ( ≥ 20 years of age for Taiwan site) * Subject with advanced…. Goal: ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702. Phase/Status/Sponsor: Unknown phase; COMPLETED; Acepodia Biotech, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) is being studied. Conditions: Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma +13 • Eligibility: Inclusion Criteria: 1. Subjects in Part A (dose escalation) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors, including the following:…. Goal: This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S is being studied. Conditions: Astrocytoma, Brain Cancer, Brain Metastases +20 • Eligibility: Inclusion Criteria: 1. Male or female participants aged ≥18 years at the time of informed consent. 2. Adequate Bone Marrow Function 3. Adequate renal function 4. Adequate Liver…. Goal: This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Quadriga Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) is being studied. Conditions: Solid Tumors • Eligibility: Inclusion Criteria for dose escalation and expansion phase: * Signed written informed consent * Male or female participants aged greater than or equal to 18 years * Participants…. Goal: This is a Phase 1, open-label, dose-escalation trial of avelumab \[antibody targeting programmed death ligand 1 (anti PD-L1)\] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Phase/Status/Sponsor: Unknown phase; COMPLETED; EMD Serono Research & Development Institute, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors is being studied. Conditions: Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC) +3 • Eligibility: Inclusion Criteria: 1. Confirmed diagnosis of advanced or metastatic select solid tumors and either progression on or documented intolerance to standard therapies 2. Age ≥ 18 years at…. Goal: To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; MedImmune LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer is being studied. Conditions: Prostate Cancer, Head & Neck Cancer, Esophageal Cancer • Eligibility: Inclusion criteria: * Patients with age ≥18 years * Confirmed diagnosis of prostate cancer, SCC esophageal cancer or head \& neck cancer * No evidence of distant spread…. Goal: The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies. Phase/Status/Sponsor: Unknown phase; COMPLETED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Application of High Resolution Diffusion-weighted MR Imaging Pulse Sequence in Head and Neck, and Prostate Cancers is being studied. Conditions: Head and Neck Cancer, Prostate Cancer • Eligibility: Inclusion Criteria: * Adults aged 18 and over. * Men and women without regard to ethnic background. * Patients/Subjects able to give informed consent * Patients/Subjects whose weight…. Goal: Magnetic resonance imaging (MRI) is a diagnostic study that makes pictures of organs of the body using magnetic field and radio frequency pulses that can not be felt. The purpose of this study is to determine if a new MR imaging method can help tumor evaluation in head and neck cancer or prostate cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT is being studied. Conditions: Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma • Eligibility: Inclusion Criteria: * Patients 18 years or older with underlying diagnosis of metastatic colorectal cancer or head and neck squamous cell carcinoma including newly diagnosed patient * Patients…. Goal: The purpose of this study is to see if the investigators can prevent or reduce the severity of the Cetuximab-related acne rash. Two different topical agents will be applied to the skin. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma is being studied. Conditions: NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: * Male or female patients ≥18 years of age. For Japan only: written consent is necessary both from the patient and his/her legal representative if he/she…. Goal: The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR. Phase/Status/Sponsor: Unknown phase; TERMINATED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer is being studied. Conditions: Head and Neck Cancer, Lung Cancer • Eligibility: Inclusion Criteria: 1. Patients with either: a) histologically proven stage I, II, or IIIa NSCLC who have undergone a complete surgical resection of the primary tumor OR b)…. Goal: Primary Objectives: 1. To examine the effect of celecoxib treatment on histological response, markers of proliferation (Ki-67), and apoptosis. Phase/Status/Sponsor: Unknown phase; TERMINATED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection is being studied. Conditions: Solid Tumors, High Grade Gliomas, Lung Cancer +4 • Eligibility: Inclusion Criteria: * The subject has been diagnosed with at least one solid primary or metastatic tumor greater than 2.0 cm in diameter, including but not limited to…. Goal: Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET acquisitions, and tumors demonstrate detectable levels of 18F uptake on PET. Phase/Status/Sponsor: Unknown phase; COMPLETED; GE Healthcare.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Rapamycin With Grapefruit Juice for Advanced Malignancies is being studied. Conditions: Tumors, Neoplasm Metastasis • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. *…. Goal: The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors is being studied. Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer +14 • Eligibility: Inclusion Criteria: To be eligible for participation in the study, patients must meet the following inclusion criteria: * Locally-advanced or metastatic solid tumor with an NRG1 gene fusion…. Goal: This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Elevation Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients is being studied. Conditions: Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma • Eligibility: Inclusion Criteria: * Patients with unresectable or metastatic melanoma including unknown primary, mucosal or uveal melanomas. Histological confirmation of melanoma will be required by previous biopsy or cytology.…. Goal: The purpose of this study is to test the safety \& efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Providence Health & Services.

This summary may be inaccurate. Verify against ClinicalTrials.gov.